A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo

Cancer Research

Volumn 66, Issue 17, 2006, Pages 8731-8739

  Shoemaker, Alex R ^a   Oleksijew, Anatol ^a   Bauch, Joy ^a   Belli, Barbara A ^b   Borre, Tony ^a   Bruncko, Milan ^a   Deckwirth, Thomas ^b   Frost, David J ^a   Jarvis, Ken ^a   Joseph, Mary K ^a   Marsh, Kennan ^a   McClellan, William ^a   Nellans, Hugh ^a   Ng, ShiChung ^a   Nimmer, Paul ^a   O'Connor, Jacqueline M ^a   Oltersdorf, Tilman ^b   Qing, Weiguo ^a   Shen, Wang ^a   Stavropoulos, Jason ^a   Tahir, Stephen K ^a   Wang, Baole ^a   Warner, Robert ^a   Zhang, Haichao ^a   Fesik, Stephen W ^a   Rosenberg, Saul H ^a   Elmore, Steven W ^a   more..

^a ABBOTT LABORATORIES   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 DIMETHYLAMINO 1 PHENYLSULFANYLMETHYLPROPYLAMINO) N [4 (4,4 DIMETHYLPIPERIDIN 1 YL)BENZOYL] 3 NITROBENZENESULFONAMIDE; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; A 385358; ANTINEOPLASTIC AGENT; CASPASE 3; CISPLATIN; CYTOTOXIC AGENT; DOXORUBICIN; ETOPOSIDE; INTERLEUKIN 3; PACLITAXEL; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG UPTAKE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MITOSIS INHIBITION; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANILINE COMPOUNDS; ANIMALS; ANTINEOPLASTIC AGENTS; BCL-X PROTEIN; BIPHENYL COMPOUNDS; CELL LINE, TUMOR; DRUG SYNERGISM; HUMANS; KINETICS; LUNG NEOPLASMS; MALE; MICE; MICE, SCID; NITROPHENOLS; PACLITAXEL; PIPERAZINES; SULFONAMIDES; TRANSPLANTATION, HETEROLOGOUS;

EID: 33749016520     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-0367     Document Type: Article

References (50)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
2. Minn AJ, Rudin CM, Boise LH, Thompson CB. Expression of bcl-xL can confer a multidrug resistance phenotype. Blood 1995;86:1903-10.
3. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002;108:153-64.
4. Bakhshi A, Jensen JP, Goldman P, et al. Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell 1985;41:899-906.
5. Espana L, Fernandez Y, Rubio N, Torregrosa A, Blanco J, Sierra A. Overexpression of Bcl-xL in human breast cancer cells enhances organ-selective lymph node metastasis. Breast Cancer Res Treat 2004;87:33-44.
6. Martin SS, Ridgeway AG, Pinkas J, et al. A cytoskeleton-based functional genetic screen identifies Bcl-xL as an enhancer of metastasis, but not primary tumor growth. Oncogene 2004;23:4641-5.
7. McDonnell TJ, Korsmeyer SJ. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14; 18). Nature 1991;349:254-6.
8. Cory S, Huang DC, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003;22:8590-607.
9. Jacobson MD, Burne JF, King MP, Miyashita T, Reed JC, Raff MC. Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA. Nature 1993;361:365-9.
10. Wei MC, Zong WX Cheng EHY, et al. Proapoptotic BAX and BAK: A requisite gateway to mitochondrial dysfunction and death. Science 2001;292:727-30.
11. Chen L, Willis SN, Wei A, et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005;17:393-403.
12. Muchmore SW, Saltier M, Liang H, et al. X-ray and NMR structure of human bcl-xl, an inhibitor of programmed cell death. Nature 1996;381:335-41.
13. Petros AM, Medek A, Nettesheim DG, et al. Solution structure of the antiapoptotic protein bcl-2. Proc Natl Acad Sci U S A 2001;98:3012-7.
14. Petros AM, Olejniczak ET, Fesik SW. Structural biology of the Bcl-2 family of proteins. Biochim Biophys Acta 2004;1644:83-94.
15. Suzuki M, Youle RJ, Tjandra N. Structure of Bax: coregulation of dimer formation and intracellular localization. Cell 2000;103:645-54.
16. Denisov AY, Madiraju MS, Chen G, et al. Solution structure of human BCL-w: modulation of ligand binding by the C-terminal helix. J Biol Chem 2003;278:21124-8.
17. Hinds MG, Lackmann M, Skea GL, Harrison PJ, Huang DC, Day CL. The structure of Bcl-w reveals a role for the C-terminal residues in modulating biological activity. EMBO J 2003;22:1497-507.
18. McDonnell JM, Fushman D, Milliman CL, Korsmeyer SJ, Cowburn D. Solution structure of the proapoptotic molecule BID: a structural basis for apoptotic agonists and antagonists. Cell 1999;96:625-34.
19. Chou JJ, Li H, Salvesen GS, Yuan J, Wagner G. Solution structure of BID, an intracellular amplifier of apoptotic signaling. Cell 1999;96:615-24.
20. Klasa RJ, Gillum AM, Klem RE, Frankel SR. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev 2002;12:193-213.
21. Wang JL, Liu DX, Zhang ZJ, et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci U S A 2000;97:7124-9.
22. Tzung SP, Kim KM, Basanez G, et al. Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nat Cell Biol 2001;3:183-91.
23. Becattini B, Sareth S, Zhai D, et al. Targeting apoptosis via chemical design: inhibition of bid-induced cell death by small organic molecules. Chem Biol 2004;11:1107-17.
24. Enyedy IJ, Ling Y, Nacro K, et al. Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. J Med Chem 2001;44:4313-24.
25. Walensky LD, Kung AL, Escher I, et al. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 2004;305:1466-70.
26. Shiau CW, Yang CC, Kulp SK, Chen KF, Chen CS, Huang JW. Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARγ. Cancer Res 2005;65:1561-9.
27. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumors. Nature 2005;435:677-81.
28. Ben-Ezra JM, Kornstein MJ, Grimes MM, Krystal G. Small cell carcinomas of the lung express the bcl-2 protein. Am J Pathol 1994;145:1036-40.
29. Olopade OI, Adeyanju MO, Safa AR, et al. Overexpression of BCL-x protein in primary breast cancer is associated with high tumor grade and nodal metastases. Cancer J Sci Am 1997;3:230-7.
30. Amundson SA, Myers TG, Scudiero D, Kitada S, Reed JC, Fornace AJ. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res 2000;60:6101-10.
31. Simonian PL, Grillot DA, Nunez G. Bcl-2 and Bel-XL can differentially block chemotherapy-induced cell death. Blood 1997;90:1208-16.
32. Fennell DA, Corbo MV, Dean NM, Monia BP, Cotter FE. In vivo suppression of Bcl-X-L expression facilitates chemotherapy-induced leukaemia cell death in a SCID/NOD-Hu model. Br J Haematol 2001;112:706-13.
33. Wendt MD, Shen W, Kunzer A. et al. Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo. J Med Chem 2006;49:1165-81.
34. Zhang HC, Nimmer P, Rosenberg SH, Ng SC, Joseph M. Development of a high-throughput fluorescence polarization assay for Bcl-x(L). Anal Biochem 2002;307:70-5.
35. Nunez G, London L, Hockenbery D, Alexander M, McKearn JP, Korsmeyer SJ. Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J Immunol 1990;144:3602-10.
36. Milas L, Milas MM, Mason KA. Combination of taxanes with radiation: preclinical studies. Semin Radiat Oncol 1999;9:12-26.
37. Harper JD, Rao PN, John PC. The mitosis-specific monoclonal antibody MPM-2 recognizes phosphoproteins associated with the nuclear envelope in Chlamydomonas reinhardtii cells. Eur J Cell Biol 1990;51:272-8.
38. Lai R, Arber DA, Chang KL, Wilson CS, Weiss LM. Frequency of bcl-2 expression in non-Hodgkin's lymphoma: a study of 778 cases with comparison of marginal zone lymphoma and monocytoid B-cell hyperplasia. Mod Pathol 1998;11:864-9.
39. Sinicrope FA, Hart J, Michelassi F, Lee JJ. Prognostic value of bcl-2 oncoprotein expression in stage II colon carcinoma. Clin Cancer Res 1995;1:1103-10.
40. McDonnell TJ, Troncoso P, Brisbay SM, et al. Expression of the proto-oncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992;52:6940-4.
41. Pratt MAC, Krajewski S, Menard M, Krajewska M, Macleod H, Reed JC. Estrogen withdrawal-induced human breast cancer tumour regression in nude mice is prevented by Bcl-2. FEBS Lett 1998;440:403-8.
42. Reed JC. Bcl-2 family proteins: regulators of chemoresistance in cancer. Toxicol Lett 1995;82/83:155-8.
43. Schmitt CA, Lowe SW. Bcl-2 mediates chemoresistance in matched pairs of primary E mu-myc lymphomas in vivo. Blood Cells Mol Dis 2001;27:206-16.
44. O'Connor PM, Jackman J, Bae I, et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 1997;57:4285-300.
45. Developmental Therapeutics Program NCI/NIH. Available from: http://dtp.nci.nih.gov/.
46. Tan TT, Degenhardt K, Nelson DA, et al. Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy. Cancer Cell 2005;7:227-38.
47. Scatena CD, Stewart ZA, Mays D, et al. Mitotic phosphorylation of Bcl-2 during normal cell cycle progression and Taxol-induced growth arrest. J Biol Chem 1998;273:30777-84.
48. Pathan N, Aime-sempe C, Kitada S, Haldar S, Reed JC. Microtubule- targeting drugs induce Bcl-2 phosphorylation and association with Pin1. Neoplasia 2001;3:70-9.
49. Poruchynsky MS, Wang EE, Rudin CM, Blagosklonny MV, Fojo T. Bcl-xL is phosphorylated in malignant cells following microtubule disruption. Cancer Res 1998;58:3331-8.
50. Fang G, Chang BS, Kim CN, Perkins C, Thompson CB, Bhalla KN. "Loop" domain is necessary for taxol-induced mobility shift and phosphorylation of Bcl-2 as well as for inhibiting taxol-induced cytosolic accumulation of cytochrome c and apoptosis. Cancer Res 1998;58:3202-8.